Payload Information
General Information of This Payload
| Payload ID | PAY0GXMDC |
|||||
|---|---|---|---|---|---|---|
| Name | QD6/B09-AZ1508 |
|||||
| Synonyms |
QD6/B09-AZ1508 payload
Click to Show/Hide
|
|||||
| Target(s) | Microtubule (MT) | |||||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
QD6/B09-AZ1508 [Investigative]
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0.00% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST1035B) | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0.00% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST551C) | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0.00% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST1328) | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0.00% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST2081) | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0.00% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST1749) | ||||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0.00% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST751) | ||||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0.00% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST935B) | ||||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0.00% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST551) | ||||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0.00% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST1506) | ||||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0.00% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST374) | ||||
| Experiment 11 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0.00% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST599) | ||||
| Experiment 12 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0.00% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST1976B) | ||||
| Experiment 13 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0.00% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST115) | ||||
| Experiment 14 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0%-20% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST1092) | ||||
| Experiment 15 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0%-20% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST2495) | ||||
| Experiment 16 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0%-20% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST1885) | ||||
| Experiment 17 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0%-20% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST1989) | ||||
| Experiment 18 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0%-20% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST1092B) | ||||
| Experiment 19 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0%-20% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST2891) | ||||
| Experiment 20 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0.94% (Day 32) | |||
| Method Description |
To assist in the selection of the appropriate EGFR affinity combination for the EGFR-CMET bispecific ADC, high and low affinity EGFR-CMET bispecific ADCs (1 mg/kg.) were compared in an in vivo eficacy study usingthe MEDI-PANC-08 pancreatic PDX model.
|
||||
| In Vivo Model | Pancreatic PDX model (PDX: MEDI-PANC-08) | ||||
| Experiment 21 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 4.50% (Day 32) | |||
| Method Description |
To assist in the selection of the appropriate EGFR affinity combination for the EGFR-CMET bispecific ADC, high and low affinity EGFR-CMET bispecific ADCs (2 mg/kg.) were compared in an in vivo eficacy study usingthe MEDI-PANC-08 pancreatic PDX model.
|
||||
| In Vivo Model | Pancreatic PDX model (PDX: MEDI-PANC-08) | ||||
| Experiment 22 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 20%-40% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST396) | ||||
| Experiment 23 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 20%-40% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST1684) | ||||
| Experiment 24 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 20%-40% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST1151) | ||||
| Experiment 25 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 20%-40% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST379) | ||||
| Experiment 26 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 20%-40% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST1437) | ||||
| Experiment 27 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 20%-40% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST1104B) | ||||
| Experiment 28 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 35.86% (Day 32) | |||
| Method Description |
To assist in the selection of the appropriate EGFR affinity combination for the EGFR-CMET bispecific ADC, high and low affinity EGFR-CMET bispecific ADCs (3 mg/kg.) were compared in an in vivo eficacy study usingthe MEDI-PANC-08 pancreatic PDX model.
|
||||
| In Vivo Model | Pancreatic PDX model (PDX: MEDI-PANC-08) | ||||
| Experiment 29 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 40%-60% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST1035) | ||||
| Experiment 30 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 60.00% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST2822B) | ||||
| Experiment 31 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 60.00% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST1271) | ||||
| Experiment 32 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 60.00% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST698B) | ||||
| Experiment 33 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 60%-80% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST1229) | ||||
| Experiment 34 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 60%-80% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST1906) | ||||
| Experiment 35 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 60%-80% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST742) | ||||
| Experiment 36 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 60%-80% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST1243) | ||||
| Experiment 37 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 80.00% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST140) | ||||
| Experiment 38 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST137) | ||||
| Experiment 39 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST1976C) | ||||
| Experiment 40 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% | |||
| Method Description |
When tumors reached the appropriate Tumor Volume lnitiation (TVl) range (125-250 mm3), animalswere randomized into treatment and control groups and intravenous (lV) dosing was initiated (Day 0). lnitial dosing began on Day 0; animals in allgroups were dosed l.V. by weight (0.01 ml per gram; 10 ml/kg). Drug treated animals were dosed every 7days for a total of 4 doses.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer PDX model (PDX: ST2869) | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Maximum inhibition efficiency (MIE) |
0.00%
|
Negative EGFR expression (EGFR ++); Negative MET expression (MET -) | ||
| Method Description |
The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Maximum inhibition efficiency (MIE) |
5.00%
|
Low EGFR expression (EGFR ++); Moderate MET expression (MET ++) | ||
| Method Description |
The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H23 cells | CVCL_1547 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Maximum inhibition efficiency (MIE) |
12.00%
|
Moderate EGFR expression (EGFR ++); Low MET expression (MET +) | ||
| Method Description |
The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
|
||||
| In Vitro Model | Lung carcinoma | A-427 cells | CVCL_1055 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Maximum inhibition efficiency (MIE) |
29.00%
|
Moderate EGFR expression (EGFR ++); Moderate MET expression (MET ++) | ||
| Method Description |
The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
|
||||
| In Vitro Model | Minimally invasive lung adenocarcinoma | NCI-H358 cells | CVCL_1559 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Maximum inhibition efficiency (MIE) |
45.00%
|
Moderate EGFR expression (EGFR ++); Moderate MET expression (MET ++) | ||
| Method Description |
The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
|
||||
| In Vitro Model | Lung adenocarcinoma | A-549 cells | CVCL_0023 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Maximum inhibition efficiency (MIE) |
54.00%
|
High EGFR expression (EGFR +++); Moderate MET expression (MET ++) | ||
| Method Description |
The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
|
||||
| In Vitro Model | Lung adenosquamous carcinoma | NCI-H596 cells | CVCL_1571 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Maximum inhibition efficiency (MIE) |
65.00%
|
Moderate EGFR expression (EGFR ++); Moderate MET expression (MET ++) | ||
| Method Description |
The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1975 cells | CVCL_1511 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Maximum inhibition efficiency (MIE) |
66.00%
|
High EGFR expression (EGFR +++); High MET expression (MET +++) | ||
| Method Description |
The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
|
||||
| In Vitro Model | Lung adenocarcinoma | HCC827-GR-step cells | CVCL_S705 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Maximum inhibition efficiency (MIE) |
79.00%
|
High EGFR expression (EGFR +++); High MET expression (MET +++) | ||
| Method Description |
The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
|
||||
| In Vitro Model | Lung adenocarcinoma | HCC827 cells | CVCL_2063 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Maximum inhibition efficiency (MIE) |
79.00%
|
Moderate EGFR expression (EGFR ++); Moderate MET expression (MET ++) | ||
| Method Description |
The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
|
||||
| In Vitro Model | Lung mucoepidermoid carcinoma | NCI-H292 cells | CVCL_0455 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Maximum inhibition efficiency (MIE) |
80.00%
|
Moderate EGFR expression (EGFR ++); Moderate MET expression (MET ++) | ||
| Method Description |
The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1792 cells | CVCL_1495 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
33.00 pM
|
High EGFR expression (EGFR +++); High MET expression (MET +++) | ||
| Method Description |
The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
|
||||
| In Vitro Model | Lung adenocarcinoma | HCC827-GR-step cells | CVCL_S705 | ||
| Experiment 13 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
81.00 pM
|
Moderate EGFR expression (EGFR ++); Moderate MET expression (MET ++) | ||
| Method Description |
The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1792 cells | CVCL_1495 | ||
| Experiment 14 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
91.00 pM
|
Moderate EGFR expression (EGFR ++); Moderate MET expression (MET ++) | ||
| Method Description |
The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
|
||||
| In Vitro Model | Lung mucoepidermoid carcinoma | NCI-H292 cells | CVCL_0455 | ||
| Experiment 15 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
96.00 pM
|
High EGFR expression (EGFR +++); High MET expression (MET +++) | ||
| Method Description |
The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
|
||||
| In Vitro Model | Lung adenocarcinoma | HCC827 cells | CVCL_2063 | ||
| Experiment 16 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.12 nM
|
Moderate EGFR expression (EGFR ++); Moderate MET expression (MET ++) | ||
| Method Description |
The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
|
||||
| In Vitro Model | Lung adenocarcinoma | A-549 cells | CVCL_0023 | ||
| Experiment 17 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 0.17 nM | Moderate EGFR expression (EGFR ++); Moderate MET expression (MET ++) | ||
| Method Description |
The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
|
||||
| In Vitro Model | Minimally invasive lung adenocarcinoma | NCI-H358 cells | CVCL_1559 | ||
| Experiment 18 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.18 nM
|
Moderate EGFR expression (EGFR ++); Moderate MET expression (MET ++) | ||
| Method Description |
The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1975 cells | CVCL_1511 | ||
| Experiment 19 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.27 nM
|
High EGFR expression (EGFR +++); Moderate MET expression (MET ++) | ||
| Method Description |
The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
|
||||
| In Vitro Model | Lung adenosquamous carcinoma | NCI-H596 cells | CVCL_1571 | ||
| Experiment 20 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
3.48 nM
|
Moderate EGFR expression (EGFR ++); Moderate MET expression (MET ++); | ||
| Method Description |
The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay. In the representative experiment, pre-treatment of NCI-H1975 cells with MET IgG RAA22.
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1975 cells | CVCL_1511 | ||
| Experiment 21 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
6.96 nM
|
Moderate EGFR expression (EGFR ++); Low MET expression (MET +) | ||
| Method Description |
The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
|
||||
| In Vitro Model | Lung carcinoma | A-427 cells | CVCL_1055 | ||
| Experiment 22 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
20.50 nM
|
Moderate EGFR expression (EGFR ++); Moderate MET expression (MET ++); | ||
| Method Description |
The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay. In the representative experiment, pre-treatment of NCI-H1975 cells with MET IgG B09.
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1975 cells | CVCL_1511 | ||
| Experiment 23 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 60.00 nM | Low EGFR expression (EGFR ++); Moderate MET expression (MET ++) | ||
| Method Description |
The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H23 cells | CVCL_1547 | ||
| Experiment 24 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 60.00 nM | Negative EGFR expression (EGFR ++); Negative MET expression (MET -) | ||
| Method Description |
The in vitro potency of EGFR/CMET bispecific ADC's was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.